killer cell lectin like receptor F1Genealiases: CLEC5C · NKp80
Q-omics provides the consensus-scored KLRF1 profile across patient tissues and cancer cell-line models. KLRF1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLRF1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, KLRF1 RNA expression shows 10,876 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where KLRF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLRF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLRF1 survival associations across molecular data types. KLRF1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLRF1 RNA expression–survival associations across cancer types. High KLRF1 expression shows favorable associations in KIRC, HNSC, SKCM, UCS, ESCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLRF1 RNA expression.
This table summarizes KLRF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KLRF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLRF1 shows lower tumor expression in COAD, LUSC, LUAD, HNSC, KIRP and LIHC. The COAD box plot shows higher KLRF1 RNA expression in normal versus tumor tissue (log2 FC = −1.074, t-test p < 0.001).
This table shows molecular features associated with KLRF1 in patient tissues and cancer cell lines. In patient samples, KLRF1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KLRF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
